Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-1RAP CAR NK cells
- Development stage
- Preclinical
- Lead developer
- New York Medical College
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-1RAP CAR NK cells are an investigational cell therapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting the interleukin-1 receptor accessory protein (IL-1RAP). IL-1RAP is a co-receptor for IL-1, IL-33, and IL-36, and is highly expressed on acute myeloid leukemia (AML) cells and leukemic stem cells, while being absent on normal hematopoietic stem cells, making it a promising target for immunotherapy. These CAR NK cells are designed to induce targeted cytotoxicity against AML cells. Research led by Mitchell S. Cairo and colleagues has explored enhancing the activity of these cells using IL-15 agonists like NKTR-255 or tri-specific killer cell engagers (TriKEs) such as cam161533 to improve persistence and potency.
- Other names
- IL-1RAP.CAR NK cellsIL1RAP.CAR NK cellsIL 1RAP.CAR NK cells
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on IL-1RAP CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-1RAP CAR NK cells.